Recovery & Tissue Repair · Reviewed by Ian K. Tseng, MD

What Is TB-500? Thymosin Beta-4, Explained

TB-500 is usually mentioned in the same breath as BPC-157, and the two are in fact frequently paired in recovery protocols. It is also the compound in this category most likely to end an athletic career by accident, because it sits on the WADA prohibited list and a great many people who take it do not know that. Here is the whole picture.

Published August 4, 2026 · Medical review by Ian K. Tseng, MD, Medical Director

Thymosin beta-4 and the fragment

Thymosin beta-4 is a naturally occurring protein of 43 amino acids found broadly in human tissue and in wound fluid. Its best-characterized biological role is binding actin — the protein that forms much of the cell's internal scaffolding — and regulating its assembly. Because actin dynamics underlie cell movement, thymosin beta-4 is involved in processes where cells need to migrate, including wound repair.

TB-500 is not thymosin beta-4 itself. It is a synthetic peptide corresponding to a short region of the parent molecule containing the actin-binding site. The distinction matters because research conducted on full thymosin beta-4 is often cited as though it establishes the properties of the fragment, which is not a sound inference.

What the research examines

Preclinical work has examined thymosin beta-4 and related fragments for effects on angiogenesis, cell migration, inflammation modulation, and tissue repair in models including cardiac, corneal, and dermal injury. Some of this research is genuinely interesting and has been pursued in clinical development programs for specific indications.

That said, the body of evidence supporting the uses TB-500 is marketed for online — athletic recovery, soft-tissue injury healing in otherwise healthy adults — is thin, and largely does not consist of controlled human trials in that population. As with any compound in this space, preclinical promise and demonstrated human benefit are different categories of claim.

If you are a tested athlete, stop here

TB-500 appears on the World Anti-Doping Agency Prohibited List. Any athlete subject to WADA-code testing — competitive, collegiate, professional, or Olympic-pathway — risks a sanction from its use, regardless of how it was obtained, whether it was prescribed, or whether they knew it was prohibited.

This is not a footnote. Anti-doping rules operate on strict liability: what is in your sample is your responsibility. A legitimate prescription from a licensed physician does not change the finding. If you compete under a testing regime, this compound is a problem for you specifically, and any provider who does not raise that before prescribing it has not done their job.

Any athlete under a testing regime should disclose their competitive status to any prescribing clinician, because it changes what is appropriate.

A regulatory status that moved in 2026

TB-500's compounding status shifted alongside BPC-157's, and the timeline is worth stating precisely because most of what is written online predates it.

The relevant bulk substance had been restricted under the FDA's 503A framework on the basis of insufficient safety characterization. On April 22, 2026 the FDA removed a group of peptides including TB-500-related substances from Category 2. On July 23, 2026 the Pharmacy Compounding Advisory Committee voted to recommend TB-500 for inclusion on the 503A Bulks List, 8 to 6 with one abstention.

That recommendation is advisory rather than binding. Formal inclusion requires FDA notice-and-comment rulemaking, typically a year or more, and the agency can depart from committee recommendations. The accurate description today: a compounded preparation that is not FDA-approved, no longer in the significant-safety-risk category, with a favorable advisory recommendation and rulemaking pending. The same picture applies to BPC-157.

The gray market problem, which has not changed

TB-500 is readily available online under the "research use only" or "not for human consumption" label. That label is the legal mechanism enabling sale outside the prescription framework — no prescription, no physician evaluation, no purity standard verified for human administration, no dosing guidance from human data, and no accountability.

For an athlete, stack the anti-doping exposure on top of that. For anyone, the underlying problem is the one we describe in are peptides safe?: a Certificate of Analysis tells you what is in the vial and nothing about whether it belongs in you.

How clinicians who prescribe it approach it

In the recovery literature TB-500 is commonly discussed alongside BPC-157 as a paired approach, used in defined cycles rather than continuously, with the target symptom or function tracked from baseline so response can be evaluated honestly at the end of a cycle.

It is framed as an adjunct to standard care — rest, rehabilitation, physical therapy, and proper diagnostic workup — not a substitute for any of them. Active or prior malignancy is a contraindication given the pro-angiogenic mechanism; pregnancy and breastfeeding are exclusions. Baseline bloodwork is standard before any repair-signalling therapy, as covered in our bloodwork explainer.

Related reading

• What Is BPC-157
• What Is MOTS-c
• Why Peptide Therapy Starts With Bloodwork
• How the Soothe IV peptide therapy program works

Frequently asked questions

This article is educational and is not medical advice. Statements have not been evaluated by the FDA. Peptide therapy is a physician-supervised medical service; specific protocols are determined individually after a Good Faith Examination and bloodwork, and not all applicants qualify. Some compounded medications used in physician-prescribed protocols are not FDA-approved. Data from clinical trials on FDA-approved medications should not be used to make assessments related to compounded medications. Soothe IV's peptide program is available nationwide via telehealth; prescriptions are issued by physicians licensed in your state.